Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years
Titel:
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years
Auteur:
Herold, Kevan C. Gitelman, Stephen Greenbaum, Carla Puck, Jennifer Hagopian, William Gottlieb, Peter Sayre, Peter Bianchine, Peter Wong, Emelita Seyfert-Margolis, Vicki Bourcier, Kasia Bluestone, Jeffrey A.